Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Forxiga

NCT ID: NCT02561130

Last Updated: 2020-11-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 154 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-12-31
• Study Completion Date: 2018-12-31

Brief Summary

The purpose of the study is to determine whether in patients with early type 2 diabetes, a short-term intensive metabolic intervention comprising Forxiga, metformin, basal insulin glargine and lifestyle approaches will be superior to standard diabetes therapy in achieving sustained diabetes remission.

Detailed Description

This is a multicentre, open-label, randomized controlled trial in 152 patients with recently-diagnosed T2DM. Participants will be randomized to 2 treatment groups: (a) a 12-week course of treatment with Forxiga, metformin, insulin glargine and lifestyle therapy, and (b) standard diabetes therapy, and followed for a total of 64 weeks (1 year and 3 months). In all participants with HbA1C<7.3% at the 12 week visit, glucose-lowering medications will be discontinued and participants will be encouraged to continue with lifestyle modifications and regular glucose monitoring. Participants with HbA1C ≥ 7.3% at this visit or who experience hyperglycemia relapse after stopping drugs will receive standard glycemic management as informed by the current Canadian Diabetes Association clinical practice guidelines.

Conditions

Type 2 Diabetes Mellitus

Keywords

Diabetes; Insulin; Glargine; Metformin; Forxiga; Diet; Exercise; Lifestyle

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Intervention

Drug: insulin glargine - sc injection; Drug: metformin, oral administration; Drug: forxiga, oral administration; Behavioral: lifestyle therapy, diet and exercise

Group Type: EXPERIMENTAL

insulin glargine

Intervention Type: DRUG

Dose is titrated to achieve fasting normoglycemia

metformin

Intervention Type: DRUG

Dose is titrated to 1 g bid or maximal tolerated dose

Forxiga

Intervention Type: DRUG

Dose is titrated to 10 mg po daily or maximal tolerated dose

Lifestyle therapy

Intervention Type: BEHAVIORAL

Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving

Standard Care

Standard glycemic care as informed by the current clinical practice guidelines

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

insulin glargine

Dose is titrated to achieve fasting normoglycemia

Intervention Type: DRUG

metformin

Dose is titrated to 1 g bid or maximal tolerated dose

Intervention Type: DRUG

Forxiga

Dose is titrated to 10 mg po daily or maximal tolerated dose

Intervention Type: DRUG

Lifestyle therapy

Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving

Intervention Type: BEHAVIORAL

Other Intervention Names

Lantus; dapagliflozin; diet and exercise

Eligibility Criteria

Inclusion Criteria

1. men and women 30-80 years of age inclusive;

2. type 2 diabetes mellitus diagnosed by a physician within 8 years prior to patient enrollment;

3. anti-diabetic drug regimen (either drug or dose of drug) unchanged during 8 weeks prior to screening and randomization;

4. HbA1C 6.5-9.5% inclusive on no hypoglycemic agents or HbA1C ≤ 8.0% on up to 2 glucose-lowering agents;

5. body mass index ≥ 23 kg/m2;

6. ability and willingness to perform self-monitoring of capillary blood glucose (SMBG);

7. ability and willingness to self-inject insulin;

8. provision of informed consent.

Exclusion Criteria

1. current use of insulin therapy;

2. history of hypoglycemia unawareness, or severe hypoglycemia requiring assistance;

3. history of end-stage renal disease or renal dysfunction as evidenced by eGFR<60 mL/min/1.73 m2 by MDRD formula;

4. history of lactic acidosis or diabetic ketoacidosis;

5. active liver disease or elevated alanine transferase (ALT) levels ≥ 2.5 times upper limit of normal at the time of enrollment;

6. history of bladder cancer or undiagnosed hematuria;

7. history of breast cancer;

8. history of polycythemia;

9. evidence of volume depletion or hypotension (systolic blood pressure < 90 mmHg);

10. systolic blood pressure > 180 mmHg or diastolic blood pressure > 105 mmHg;

11. diagnosed cardiovascular disease (unless cleared for a moderate intensity exercise program by a specialist) including:

1. any history of acute coronary syndrome, hospitalization for unstable angina, myocardial infarction, or revascularization with coronary artery bypass grafting or percutaneous coronary intervention;

2. other evidence of coronary artery disease;

3. peripheral vascular disease, valvular heart disease, cardiomyopathy, aortic dissection, tachyarrhythmias, bradyarrhythmias, prior stroke or TIA;

4. prior hospitalization for heart failure; or

5. ECG findings concerning for ischemic heart disease (i.e. pathological Q-waves, ST-segment-T-wave abnormalities in contiguous leads, left anterior hemiblock, left bundle branch block, second or third degree atrioventricular block).

12. dependence on oxygen;

13. history of any disease requiring frequent intermittent or continuous systemic glucocorticoid treatment;

14. history of bariatric surgery, or planned bariatric surgery in the next 1.5 years;

15. history of any major illness with a life expectancy of < 3 years;

16. history of injury or any other condition that significantly limits participant's ability to achieve moderate levels of physical activity;

17. any history of excessive alcohol intake, acute or chronic;

18. currently pregnant, or breastfeeding, or not using a reliable method of birth control for the duration of the trial in all females with childbearing potential; reliable methods of birth control include oral contraceptive (birth control pill), hormonal injection, implant, patch, or vaginal ring, intrauterine device, barrier method (condom and spermicide), tubal ligation, partner vasectomy or abstinence;

19. known hypersensitivity to metformin, Forxiga, or insulin glargine.

• Minimum Eligible Age: 30 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

AstraZeneca

INDUSTRY

Sponsor Role: collaborator

Population Health Research Institute

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Natalia McInnes, MD

Role: PRINCIPAL_INVESTIGATOR

McMaster University

Hertzel C Gerstein, MD

Role: STUDY_CHAIR

Hamilton Health Sciences Corporation

Locations

University of Calgary

Calgary, Alberta, Canada

Health Science Centre

Winnipeg, Manitoba, Canada

McMaster University

Hamilton, Ontario, Canada

St. Joseph's Hospital

London, Ontario, Canada

Western University

London, Ontario, Canada

LMC

Toronto, Ontario, Canada

St. Michaels's Hospital

Toronto, Ontario, Canada

Countries

Canada

References

McInnes N, Hall S, Sultan F, Aronson R, Hramiak I, Harris S, Sigal RJ, Woo V, Liu YY, Gerstein HC. Remission of Type 2 Diabetes Following a Short-term Intervention With Insulin Glargine, Metformin, and Dapagliflozin. J Clin Endocrinol Metab. 2020 Aug 1;105(8):dgaa248. doi: 10.1210/clinem/dgaa248.

Reference Type: DERIVED

PMID: 32403130 (View on PubMed)

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

REMIT-Dapa

Identifier Type: -

Identifier Source: org_study_id